Concepedia

Author

Georg Kralidis

Novartis (Switzerland)

Also Known As

Delphine Héquet, G. Kralidis, GEORG KRALIDIS, Georg Kralidis, Kralidis, G

13

Publications

695

Citations

10

H-Index

13

Concepts

All Affiliations

Novartis (Switzerland)University Hospital of ZurichUniversity Hospital of LausanneAalborg University HospitalUniversity Hospital of Bern
GK

About

Georg Kralidis is an author at Novartis (Switzerland) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

112

2

Pharmacology

2

2

112

3

Health Sciences

1

1

31

4

Anesthesia

1

1

31

5

Drug Discovery

1

1

31

Georg Kralidis

×

9

Publications

668

Citations

9

H-Index

YearCitations

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M <sub>3</sub> selective receptor antagonist, in the treatment of overactive bladder

Christopher R. Chapple, William D. Steers, Peggy Norton,

British Journal of Urology

2005

131

Impact of Antiviral Preventive Strategies on the Incidence and Outcomes of Cytomegalovirus Disease in Solid Organ Transplant Recipients

Oriol Manuel, Georg Kralidis, Nicolas J. Mueller,

American Journal of Transplantation

2013

113

Long-term Results of Surgery For Urethral Stricture: A Statistical Analysis

Thomas M. Kessler, F. Schreiter, Georg Kralidis,

The Journal of Urology

2003

96

An investigation of dose titration with darifenacin, an M <sub>3</sub> ‐selective receptor antagonist

William D. Steers, Jacques Corcos, Jenelle E. Foote,

British Journal of Urology

2005

92

Treatment of Overactive Bladder in the Older Patient: Pooled Analysis of Three Phase III Studies of Darifenacin, an M3 Selective Receptor Antagonist

Jenelle E. Foote, Karin Glavind, Georg Kralidis,

European Urology

2005

81

Impact of enterococcal colonization and infection in solid organ transplantation recipients from the Swiss Transplant Cohort Study

E. Bucheli, Georg Kralidis, Katia Boggian,

Transplant Infectious Disease

2013

43

Cancer‐related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double‐blind, noninferiority trial

Marie‐Henriette Eerdekens, Sofia Kapanadze, E. Dietlind Koch,

European Journal of Pain

2018

41

Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis

Piet Geusens, Rieke Alten, Jozef Rovenský,

International Journal of Clinical Practice

2004

40

Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks

E. Dietlind Koch, Sofia Kapanadze, Marie‐Henriette Eerdekens,

Journal of Pain and Symptom Management

2019

31

Page 1